FDA Brief

Warning letters Devices

FDA warning letter to

Chirp Innovations, LLC

High riskIssued Oct 2Posted Oct 27Center for Devices and Radiological Health

FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

What happened

FDA inspected Chirp Innovations’ facility in Lehi, Utah, from November 18 to 21, 2025, and reviewed the company’s website and marketing materials. The agency found no documented quality-system procedures for management review, quality audits, design controls, purchasing controls, corrective and preventive actions, or complaint files. It also found no medical device reporting (MDR) procedure to evaluate complaints for adverse events, and it found the Halo device promoted for menstrual pain outside its cleared indications without required clearance or approval.

What FDA found

  1. The company lacked documented procedures for management review and quality audits.

    21 CFR 820.5; 21 CFR 820.20; 21 CFR 820.22
  2. The company lacked documented design controls.

    21 CFR 820.30
  3. The company lacked documented purchasing controls.

    21 CFR 820.50
  4. The company lacked documented corrective and preventive action procedures and complaint-file procedures.

    21 CFR 820.100; 21 CFR 820.198
  5. The company lacked written medical device reporting procedures to evaluate complaints for adverse events.

    21 CFR 803.17
  6. The company promoted the Halo device for menstrual pain outside its cleared indications without required clearance or approval.

    section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); section 502(o), 21 U.S.C. § 352(o); 21 CFR 807.81(a)(3)(ii)

What FDA wants

FDA tells Chirp to respond in writing within 15 business days with the specific steps taken, corrective actions to prevent recurrence, and the actual quality-system and MDR procedures. If corrections cannot be completed in that time, the company must give the reason and a timetable.

Who should pay attention

  • makers of over-the-counter TENS/EMS devices
  • companies that market devices beyond cleared indications
  • quality teams at small device firms using outside consultants

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  2. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk